文献速递肝胆胰外科

荷兰胰腺癌诊疗最佳实践的实施:一项阶梯楔形随机临床试验

Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial.
PubMed 文献 · JAMA Surg · 2024-01-01

该多中心阶梯楔形整群随机试验纳入荷兰5887例胰腺导管腺癌患者,比较强化实施5项最佳实践与常规诊疗,干预后1年生存率为24% vs 23%(HR 0.98,95%CI 0.88-1.08),EORTC整体健康评分未改善,但姑息化疗、胰腺酶替代治疗和金属胆道支架使用增加。

要点

  • 强化实施最佳实践未改善1年生存(24% vs 23%,HR 0.98,95%CI 0.88-1.08)。
  • 姑息化疗、胰腺酶替代治疗和金属胆道支架使用显著增加。
  • EORTC整体健康评分未改善(AUC 43.9 vs 42.8,中位差-1.09,95%CI -3.05至0.94)。

核心结论

  • 在胰腺癌诊疗中实施5项最佳实践未改善1年生存率和生活质量。
  • 多数患者未接受针对肿瘤的治疗且生存率低,凸显需要更个体化的治疗选择。

研究设计与样本

  • 多中心阶梯楔形整群随机临床试验,比较强化实施最佳实践与常规诊疗。
  • 纳入荷兰全部经病理或临床诊断的胰腺导管腺癌连续患者,共5887例,中位年龄72.0岁(IQR 64.0-79.0),女性50%。
  • 研究期间为2018年5月22日至2020年7月9日,报告1年随访(死亡患者随访更短)。
  • 在全部17个荷兰胰腺癌诊疗网络中按随机顺序完成为期6周的实施期。

主要发现

  • 1年生存率干预后24% vs 干预前23%(HR 0.98,95%CI 0.88-1.08)。
  • 新辅助化疗使用率11% vs 11%,辅助化疗48% vs 51%,转诊营养师59% vs 63%,均无差异。
  • 姑息化疗使用率24% vs 30%(OR 1.38,95%CI 1.10-1.74),胰腺酶替代治疗34% vs 45%(OR 1.64,95%CI 1.28-2.11),金属胆道支架74% vs 83%(OR 1.78,95%CI 1.13-2.80),均增加。
  • EORTC整体健康评分未改善(曲线下面积43.9 vs 42.8;中位差-1.09,95%CI -3.05至0.94)。

关键数值与推荐

  • 5项最佳实践包括:优化围手术期化疗、姑息化疗、胰腺酶替代治疗(PERT)、转诊营养师、胆道梗阻患者使用金属支架。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Implementation of new cancer treatment strategies as recommended by evidence-based guidelines is often slow and suboptimal. OBJECTIVE: To improve the implementation of guideline-based best practices in the Netherlands in pancreatic cancer care and assess the impact on survival. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, stepped-wedge cluster randomized trial compared enhanced implementation of best practices with usual care in consecutive patients with all stages of pancreatic cancer. It took place from May 22, 2018 through July 9, 2020. Data were analyzed from April 1, 2022, through February 1, 2023. It included all patients in the Netherlands with pathologically or clinically diagnosed pancreatic ductal adenocarcinoma. This study reports 1-year follow-up (or shorter in case of deceased patients). INTERVENTION: The 5 best practices included optimal use of perioperative chemotherapy, palliative chemotherapy, pancreatic enzyme replacement therapy (PERT), referral to a dietician, and use of metal stents in patients with biliary obstruction. A 6-week implementation period was completed, in a randomized order, in all 17 Dutch networks for pancreatic cancer care. MAIN OUTCOMES AND MEASURES: The primary outcome was 1-year survival. Secondary outcomes included adherence to best practices and quality of life (European Organisation for Research and Treatment of Cancer [EORTC] global health score). RESULTS: Overall, 5887 patients with pancreatic cancer (median age, 72.0 [IQR, 64.0-79.0] years; 50% female) were enrolled, 2641 before and 2939 after implementation of best practices (307 during wash-in period). One-year survival was 24% vs 23% (hazard ratio, 0.98, 95% CI, 0.88-1.08). There was no difference in the use of neoadjuvant chemotherapy (11% vs 11%), adjuvant chemotherapy (48% vs 51%), and referral to a dietician (59% vs 63%), while the use of palliative chemotherapy (24% vs 30%; odds ratio [OR], 1.38; 95% CI, 1.10-1.74), PERT (34% vs 45%; OR, 1.64; 95% CI, 1.28-2.11), and metal biliary stents increased (74% vs 83%; OR, 1.78; 95% CI, 1.13-2.80). The EORTC global health score did not improve (area under the curve, 43.9 vs 42.8; median difference, -1.09, 95% CI, -3.05 to 0.94). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, implementation of 5 best practices in pancreatic cancer care did not improve 1-year survival and quality of life. The finding that most patients received no tumor-directed treatment paired with the poor survival highlights the need for more personalized treatment options. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03513705.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Mackay TM, Latenstein AEJ, Augustinus S, et al. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. JAMA Surg. 2024. PMID: 38353966. doi:10.1001/jamasurg.2023.7872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。